Eisai shares plunge 12% on report linked to Biogen drug

57
1
Eisai shares plunge 12% on report linked to Biogen drug

In about 16 months, Eisai shares fell the most after a report that a second death could be linked to the groundbreaking experimental drug for Alzheimer's disease it is developing with Biogen.

A 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, according to a report in Science magazine. The report said that the bleeding began after the patient received an anti-clotting drug. Brain swelling and bleeding have been linked to medicines that work like the Biogen-Eisai treatment.

Eisai shares plunged by 12% in Tokyo Tuesday, the largest intraday drop since July 16 last year. Biogen fell by 4.3% in New York on Monday, the most since Sept. 29.

This could be due to a conflict with your ad blocking or security software. There are jp and piano.io on the list of allowed sites. If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this FAQ. We humbly apologize for the inconvenience.